Leukemia

MD Anderson Cancer Center Publication Shows How Bionano’s Saphyr System Can Significantly Reduce Time to Actionable Results for Myelodysplastic Syndrome Patients

Tuesday, January 19, 2021 - 1:00pm

MDS is a precursor to Acute Myeloid Leukemia and structural variation analysis is important for clinical management of patients with MDS.

Key Points: 
  • MDS is a precursor to Acute Myeloid Leukemia and structural variation analysis is important for clinical management of patients with MDS.
  • Several tests are run sequentially after initial data analysis to confirm gene-specific variants, leading to a diagnostic process that can span several weeks.
  • In this study, Dr. Kanagal-Shamanna evaluated the performance of OGM in a series of 12 previously well-characterized MDS cases using clinical bone marrow samples.
  • Erik Holmlin, PhD, CEO of Bionano Genomics, commented: The MD Anderson Cancer Center is one of the worlds most important cancer research and treatment centers.

Worldwide Hairy Cell Leukemia Drugs Industry to 2025 - Cumulative Impact of COVID-19

Thursday, January 14, 2021 - 9:15pm

This research report categorizes the Hairy Cell Leukemia Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Key Points: 
  • This research report categorizes the Hairy Cell Leukemia Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product Type, the Hairy Cell Leukemia Drugs Market is examined across Chemotherapy Drug and Immunotherapy Drug.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Hairy Cell Leukemia Drugs Market during the forecast period?
  • What are the technology trends and regulatory frameworks in the Global Hairy Cell Leukemia Drugs Market?
  • What are the modes and strategic moves considered suitable for entering the Global Hairy Cell Leukemia Drugs Market?

Global Hairy Cell Leukemia Drugs Market (2020 to 2025) - by Product Type and Distribution Channel - ResearchAndMarkets.com

Thursday, January 14, 2021 - 10:51am

What is the market size and forecast of the Global Hairy Cell Leukemia Drugs Market?

Key Points: 
  • What is the market size and forecast of the Global Hairy Cell Leukemia Drugs Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Hairy Cell Leukemia Drugs Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hairy Cell Leukemia Drugs Market?
  • What are the modes and strategic moves considered suitable for entering the Global Hairy Cell Leukemia Drugs Market?

Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates

Wednesday, January 13, 2021 - 12:00pm

The Company has initiated the technology transfer process and expects the cGMP manufacturing facility to be fully operational in the first half of 2021.

Key Points: 
  • The Company has initiated the technology transfer process and expects the cGMP manufacturing facility to be fully operational in the first half of 2021.
  • "With the recent initiation of our Phase 2 study in post-transplant AML, this new facility will assist with the timely manufacture of MT-401.
  • The manufacturing of Marker's MultiTAA-specific T cell therapy for AML begins with collecting T cells from healthy donors.
  • As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors

Monday, January 11, 2021 - 9:01pm

I am very pleased to welcome Marina to our Board of Directors, stated Filippo Petti, CEO of Celyad Oncology.

Key Points: 
  • I am very pleased to welcome Marina to our Board of Directors, stated Filippo Petti, CEO of Celyad Oncology.
  • Dr. Marina Udier said, Celyad Oncology is at a pivotal moment in its company history with multiple candidates in the clinic and a promising array of significant milestones expected in 2021.
  • Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.

GRAIL Announces Collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to Evaluate Cancer Early Detection Technology for Minimal Residual Disease

Monday, January 11, 2021 - 1:30pm

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAILs methylation-based technology for the detection of minimal residual disease (MRD).

Key Points: 
  • GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NASDAQ:AMGN), AstraZeneca (LSE/STO/Nasdaq: AZN), and Bristol Myers Squibb (NYSE: BMY) to evaluate GRAILs methylation-based technology for the detection of minimal residual disease (MRD).
  • Cancer MRD testing is used in clinical and research applications to detect the presence or absence of residual disease.
  • Cancer never quits, making the detection of residual disease and early recurrences critical to helping patients and care providers stay ahead of the disease.
  • GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection.

Starton Therapeutics Selects Formulation for Continuous Subcutaneous Lenalidomide Delivery System for CLL Treatment

Monday, January 11, 2021 - 12:40pm

PARAMUS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (Starton or the Company), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced today that it has selected a subcutaneous lenalidomide formulation as the lead formulation candidate for its continuous subcutaneous delivery system (STAR-LLD SC) for chronic lymphocytic leukemia (CLL) and other hematologic malignancies.

Key Points: 
  • PARAMUS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (Starton or the Company), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced today that it has selected a subcutaneous lenalidomide formulation as the lead formulation candidate for its continuous subcutaneous delivery system (STAR-LLD SC) for chronic lymphocytic leukemia (CLL) and other hematologic malignancies.
  • STAR-LLD SC is the first delivery system in the STAR-LLD continuous delivery platform.
  • Starton is also developing a once-weekly transdermal delivery patch system, which is also rapidly progressing in formulation development.
  • Starton uses proven continuous delivery technology with proprietary drivers to obtain new indications or develop on-label superiority for patients with hematological malignancies.

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

Thursday, January 7, 2021 - 11:10am

The BTD is part of the revised Drug Registration Regulation that became effective in July 2020 in China.

Key Points: 
  • The BTD is part of the revised Drug Registration Regulation that became effective in July 2020 in China.
  • In 2017, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for treatment of adults with relapsed or refractory AML.
  • Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow.
  • Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease.

APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

Thursday, January 7, 2021 - 12:10pm

Discovered and developed by GlycoMimetics, uproleselan (APL-106) is a late clinical-stage, potentially first-in-class, targeted inhibitor of E-selectin.

Key Points: 
  • Discovered and developed by GlycoMimetics, uproleselan (APL-106) is a late clinical-stage, potentially first-in-class, targeted inhibitor of E-selectin.
  • In 2017, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for treatment of adults with relapsed or refractory AML.
  • Apollomics licensed APL-106 from GlycoMimetics in January 2020 to develop and commercialize APL-106 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.
  • Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow.

Pacylex Pharmaceuticals Announces Publication in Breast Cancer Research and Treatment of a New Target for Therapeutic Intervention in Breast Cancer and Preclinical Results of a First-in-Class Therapy

Wednesday, January 6, 2021 - 8:34pm

Pacylex is developing this NMT inhibitor, PCLX-001, as a first in class therapy for various leukemias and lymphomas and also plans to study its effects on various solid tumors.

Key Points: 
  • Pacylex is developing this NMT inhibitor, PCLX-001, as a first in class therapy for various leukemias and lymphomas and also plans to study its effects on various solid tumors.
  • To view the full announcement, including downloadable images, bios, and more, click here .
  • Pacylex is a pre-clinical pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, and is headquartered in Edmonton, Alberta, Canada.
  • PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling us to exploit NMTs as new clinical targets for cancer treatment.